Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.

Zhou P, Tan Y, Hao Z, Xu W, Zhou X, Yu J

Open source

DOI
10.3389/fendo.2023.1144838
Published
2023
Container
Frontiers in endocrinology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fendo.2023.1144838,
  title = {Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.},
  author = {Zhou P and Tan Y and Hao Z and Xu W and Zhou X and Yu J},
  year = {2023},
  journal = {Frontiers in endocrinology},
  doi = {10.3389/fendo.2023.1144838},
  url = {https://doi.org/10.3389/fendo.2023.1144838}
}

RIS

TY  - JOUR
TI  - Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.
AU  - Zhou P
AU  - Tan Y
AU  - Hao Z
AU  - Xu W
AU  - Zhou X
AU  - Yu J
PY  - 2023
JO  - Frontiers in endocrinology
DO  - 10.3389/fendo.2023.1144838
UR  - https://doi.org/10.3389/fendo.2023.1144838
ER  - 

APA

P, Z., Y, T., Z, H., W, X., X, Z., & J, Y. (2023). Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2023.1144838

Source records